FDA approves drug that can delay onset of T1D

The FDA has now approved the use of teplizumab (Tzield), the world’s first ever immunotherapy for Type 1 diabetes, by people at risk of Type 1 diabetes.

A clinical trial found that teplizumab can delay Type 1 diabetes by an average of three years in people at high risk of developing the condition.

Chris Askew OBE, Chief Executive at Diabetes UK, said: “Today’s landmark approval of teplizumab in the US is the start of a seismic shift in how Type 1 diabetes is treated. For 100 years, people living with Type 1 diabetes have relied on insulin to treat the condition, and today’s decision means that for the first time, the root cause of the condition – an immune system attack – can be tackled, and Type 1 diabetes potentially delayed for up to three years.”

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags